Literature DB >> 19360923

Infliximab to treat severe ulcerative colitis.

Dídia Bisamra Cury1, Marcelo de Souza Cury, Geraldo Vinicius Hemerly Elias, Sender Jankiel Mizsputen.   

Abstract

A 48-year-old female with severe ulcerative colitis refractory to conventional therapy was referred to our facility for management. The patient showed extensive ulcerative colitis since the age of 20 years and had failed therapy with 5-aminosalicylic acid agents and azathioprine. The disease remained active despite treatment with steroids and cyclosporine. The clinical and endoscopic parameters were consistent with severe disease. Infectious precipitants were ruled out. Given the severity of the disease and in order to avoid a colectomy, we started the patient on infliximab therapy. A dramatic clinical and endoscopic response was observed and she remained in remission at the end of a 1-year follow-up period. We discuss findings in the literature regarding the use of infliximab therapy in patients with ulcerative colitis who have failed steroids and cyclosporine.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19360923      PMCID: PMC2668785          DOI: 10.3748/wjg.15.1771

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  18 in total

1.  Infliximab for patients with refractory ulcerative colitis.

Authors:  W Y Chey
Journal:  Inflamm Bowel Dis       Date:  2001-05       Impact factor: 5.325

Review 2.  American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.

Authors:  Gary R Lichtenstein; Maria T Abreu; Russell Cohen; William Tremaine
Journal:  Gastroenterology       Date:  2006-03       Impact factor: 22.682

3.  Infliximab for treatment of steroid-refractory ulcerative colitis.

Authors:  G C Actis; M Bruno; M Pinna-Pintor; F P Rossini; M Rizzetto
Journal:  Dig Liver Dis       Date:  2002-09       Impact factor: 4.088

4.  Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis.

Authors:  Chinyu Su; Bruce A Salzberg; James D Lewis; Julius J Deren; Asher Kornbluth; David A Katzka; Robert B Stein; Douglas R Adler; Gary R Lichtenstein
Journal:  Am J Gastroenterol       Date:  2002-10       Impact factor: 10.864

Review 5.  Review article: Immunosuppressants in distal ulcerative colitis.

Authors:  G Falasco; R Zinicola; Alastair Forbes
Journal:  Aliment Pharmacol Ther       Date:  2002-02       Impact factor: 8.171

Review 6.  Thiopurine therapy: when to start and when to stop.

Authors:  Dermot P B McGovern; Simon P L Travis
Journal:  Eur J Gastroenterol Hepatol       Date:  2003-03       Impact factor: 2.566

7.  Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis.

Authors:  Elana A Maser; Deepthi Deconda; Simon Lichtiger; Thomas Ullman; Daniel H Present; Asher Kornbluth
Journal:  Clin Gastroenterol Hepatol       Date:  2008-10       Impact factor: 11.382

Review 8.  Steroid-refractory severe ulcerative colitis: what are the available treatment options?

Authors:  Alan C Moss; Mark A Peppercorn
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.

Authors:  Jan M H Van den Brande; Henri Braat; Gijs R van den Brink; Henri H Versteeg; Christiaan A Bauer; Inge Hoedemaeker; Catherine van Montfrans; Daan W Hommes; Maikel P Peppelenbosch; Sander J H van Deventer
Journal:  Gastroenterology       Date:  2003-06       Impact factor: 22.682

10.  Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.

Authors:  C S J Probert; S D Hearing; S Schreiber; T Kühbacher; S Ghosh; I D R Arnott; A Forbes
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

View more
  1 in total

1.  Early aggressive therapy for severe extensive ulcerative colitis.

Authors:  De-Jun Cui
Journal:  World J Gastroenterol       Date:  2009-09-07       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.